CDK4 and breast cancer: The encouraging data from the RAD1901-005 study supported the development of the EMERALD trial, an active phase III trial comparing the efficacy and safety of elacestrant with the standard of care (SOC) ET (fulvestrant or exemestane) in patients with breast cancer who have previously received a CDK4/6 inhibitor [14].